Free Trial
LON:N4P

N4 Pharma (N4P) Share Price, News & Analysis

N4 Pharma logo
GBX 0.50 +0.03 (+5.26%)
As of 05/30/2025 05:41 AM Eastern

About N4 Pharma Stock (LON:N4P)

Key Stats

Today's Range
0.45
0.50
50-Day Range
0.36
0.60
52-Week Range
0.35
0.80
Volume
155,156 shs
Average Volume
2.39 million shs
Market Capitalization
£2.15 million
P/E Ratio
N/A
Dividend Yield
3.12%
Price Target
N/A
Consensus Rating
N/A

Company Overview

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners. N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn’s disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments. click here to visit our investor hub https://investors.n4pharma.com/

Receive N4P Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for N4 Pharma and its competitors with MarketBeat's FREE daily newsletter.

N4P Stock News Headlines

N4 Pharma PLC reports change in major holdings
N4 Pharma (LON:N4P) Shares Down 5.3% - Time to Sell?
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
N4 Pharma PLC
N4 Pharma Plc Share Chat (N4P)
N4 Pharma PLC (N4P.AQ)
See More Headlines

N4P Stock Analysis - Frequently Asked Questions

N4 Pharma's stock was trading at GBX 0.54 on January 1st, 2025. Since then, N4P shares have decreased by 6.5% and is now trading at GBX 0.50.
View the best growth stocks for 2025 here
.

N4 Pharma Plc (LON:N4P) issued its earnings results on Thursday, September, 17th. The company reported ($0.48) earnings per share for the quarter. N4 Pharma had a negative net margin of 18,399.86% and a negative trailing twelve-month return on equity of 90.68%.

Shares of N4P stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that N4 Pharma investors own include 4D pharma (DDDD), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP), Coats Group (COA), EQTEC (EQT) and genedrive (GDR).

Company Calendar

Last Earnings
9/17/2020
Today
5/31/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
LON:N4P
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£1.63 million
Net Margins
-18,399.86%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£8,841.37
Cash Flow
GBX 0.22 per share
Price / Cash Flow
2.25
Book Value
GBX 0.45 per share
Price / Book
1.12

Miscellaneous

Free Float
N/A
Market Cap
£2.15 million
Optionable
Not Optionable
Beta
-0.37
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (LON:N4P) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners